Floatz logo

Oprelvekin

Nodal Marginal Zone B-cell Lymphoma

National Cancer Institute (NCI)protein_peptidePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

38 Active assets in the Nodal Marginal Zone B-cell Lymphoma cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
SWOG Cancer Research Network
Phase 2BB
ETOPOSIDE
University of California, Davis
Phase 2BB
Fludarabine
UNC Lineberger Comprehensive Cancer Center
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
DEXAMETHASONE
Izidore Lossos, MD
Phase 2BB

View all 50 →

Same molecule, other indications

Oprelvekin is also rated in:

von Willebrand disease (hereditary or acquired)Dormant
CCC
Indicative ·
55 / 100
View asset →
hemophilia ADormant
CCC
Indicative ·
52 / 100
View asset →
marginal zone lymphomaDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →